defens natur healthcar firm offer
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
hold strong portfolio market pipelin
drug increas competit compani key drug humira
slow growth compani total sale
higher portion earn due higher margin revenu
humira key determin perform next
approv rheumatoid arthriti psoriasi crohn
diseas humira hold wide rang indic biosimilar
pressur intern market like lead declin sale
next year expect biosimilar competit
acceler declin also brand competit like
weigh humira growth next sever year particular
new jak inhibitor antibodi repres major
advanc rheumatoid arthriti psoriasi
like lead market share loss humira
well-posit next gener immunolog drug
particular pipelin drug shown improv efficaci safeti
humira current lead treatment option
beyond immunolog cancer drug imbruvica next-biggest
sale contributor imbruvica strong clinic data sever form
blood cancer lead peak sale billion
remain drug larg matur patent expir long
past manufactur specif dose complex
look forward pipelin weight toward new
cancer drug particular pipelin lead
increasingli strong posit blood cancer compani
abl leverag solid entrench imbruvica launch
new drug
beyond intern research develop effort
announc acquisit allergan bring strong cash
flow gener entiti help diversifi compani
away depend humira
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust earn includ dilut impact stock award earn per
share calcul take earn divid share count
drug compani strong exposur immunolog
oncolog compani top drug humira repres half
compani current profit compani spun abbott earli
recent announc acquisit allergan add sever new
drug aesthet women health
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
slightli lower fair valu estim
base industri review potenti
litig cost factor discount
cash flow model longer durat allergan
acquisit carri signific premium
stock price view compani under-valued
believ manag opportunist
advantag allergan low price combin need
reduc depend humira model major
annual humira declin begin outsid
 follow key patent settlement
key valuat driver off-set eventu like humira sale
declin compani next-gener immunolog
drug target jak pathway new
pathway seem offer better efficaci improv
side effect profil humira help off-set like
strong blockbust potenti leukemia also compani
sever late-stag cancer drug
help mitig eventu humira sale declin allergan
cash flow also help mitig humira pressur
bottom line next three year expect
improv margin larg driven higher contribut
total sale specialti drug carri high
margin also partnership royalti humira
began expir help improv gross margin
weight averag cost capit use cost
equiti market rate cost debt
larg base low volatil cash flow
divers inelast product portfolio rate
uncertainti medium larg line
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
competit humira immedi term potenti
gener biosimilar threat time frame
believ excess return like persist year
certain outlook
would need wide-moat rate model
humira sale declin begin rate
declin like gradual typic small
molecule-brand drug face gener competit
complex develop market biosimilar
nevertheless deriv enorm cash flow
current product portfolio fund on-going discoveri
develop next gener drug larg cash
flow creat economi scale enabl
fund averag million requir new drug
strong pharma firm
creat databas intellectu insight help
increas odd success drug develop final
entrench salesforc one
sought-aft therapeut area immunolog help
firm launch next gener drug make
firm lead candid smaller drug firm need help
develop commerci innov new drug
moat trend neg sever competit
threat target humira new brand drug
launch humira key therapeut area includ
ra psoriasi crohn diseas howev
expect humira lose high degre market share
new drug slow market eros longer term
like addit humira patent
loss like bring new competit threat gener
manufactur damag partli mitig given
biolog complex manufactur market
gener version drug also less power patent
like delay competit case amgen
sever drug compani agre
base-cas fair valu estim bull case
probabl bear case probabl
project fair valu estim rel base case
scenario analysi show moder varianc henc
medium uncertainti rate key driver compani
valuat humira unknown degre pressur
biosimilar competit humira weigh certainti
addit increas debt exposur need fund
allergan acquisit also weigh firm
uncertainti level lastli ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
believ support narrow moat base
patent-protect drug intellectu intang
power salesforc case drug firm
core moat lie portfolio patent-protect
drug howev unlik pharma peer
tend carri wide moat one drug humira repres
major sale profit
greater result emerg brand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
launch
less-pow patent keep compani bay
addit major industri headwind creat
roadblock path creat next gener
drug particular fda grown increasingli
risk-sensit approv safe drug drug
highli need area like cancer insur compani
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern around world
evalu compar effect program
aggress price negoti increas bar
need futur innov
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
support strong dividend yield
act valuat support cash flow support
dividend look secur next year
increas entrench blood cancer
bode well growth price power remain
solid therapeut area pharmaceut
osever pipelin drug immunolog
mechan action similar drug alreadi
approv take away first mover advantag
oth high profit margin humira like caus
amplifi impact earn sale lost
jak pathway help mitig
oth extra debt need financ allergan deal
could put amplifi pressur core asset
like botox humira face tougher competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit allergan significantli increas
debt expect firm net debt posit peak
close billion given strong cash flow
base busi acquir cash flow
allergan deal expect firm rapidli pay
debt still financ dividend howev
expect much room make
signific acquisit sever year capit
tie pay debt fund robust dividend
similar drug firm face risk new
drug failur reimburs challeng new drug
drug price cut larg payer group grow
concentr humira sale make compani
significantli expos new competit threat
humira biosimilar new brand drug
competit also taken signific debt
purchas allergan expect robust cash flow
help manag heavi debt load overal view firm
medium uncertainti level
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ manag team demonstr
standard stewardship fail acquisit attempt
shire concern believ new abrupt
treasuri law larg caus acquisit collaps
somewhat give manag pass nevertheless
billion break-up fee relat fail shire deal
show manag gaug polit landscap
correctli billion pharmacycl acquisit
appear fair use capit imbruvica reach
billion plu peak sale project howev billion
acquisit stemcentrx look like miss judgment
key cancer asset appear less effect late-stag
studi importantli mega-acquisit allergan
look like fair use capit help compani
reduc depend humira
turn manag specif led
gonzalez join abbott held mani
manageri post throughout career firm
howev recent led drug group start juli
brief retir rel short tenur
key field drug commerci develop
concern execut go well
leadership howev optimist long-term project
set manag team hurt credibl
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
fidel manag research compani
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
report fourth-quart result larg line
expect dont expect major chang
fair valu estim continu view stock
under-valued market fulli appreci
firm next-gener drug feel balanc new
drug offset larg hole left end exclus
immunolog drug humira on-going biosimilar launch
intern expect support
quarter oper sale growth larg
support remark strong new immunolog drug
growth continu strength hematolog drug
offset fall intern humira global hepat
 sale larg expect trend continu
intern biosimilar pressur humira
erod sale also believ market
opportun hepat drug shrink due
cur natur drug howev psoriasi drug skyrizi
rheumatoid arthriti drug rinvoq post strong
growth guidanc billion combin sale
drug look achiev base lead efficaci
favor market posit support strong
entrench humira relat indic
pipelin side continu make strong
progress heavi focu expand indic
current market drug particular expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
approv rinvoq atop dermat psoriat arthriti
ankylos spondyl doubl market
potenti drug also expect imbruvica expand
leukemia approv broader patient popul
includ younger fit patient lastli like
approv orilissa uterin fibroid open much
turn acquisit allergan deal remain
track close end first quarter dont expect
close impact valuat
concern around price pressur pharmaceut
believ hold price concern around cost
effect specif humira abbvi
overal price posit aspect esg includ
legal issu pleas see recent healthcar observ
esg risk affect moat valuat pharma
morningstar sustainalyt offer complementari
valuat chang healthcar
make chang fair valu estim
within healthcar coverag result novel
outbreak scientist
physician grappl find treatment vaccin
investor eager find firm
promis technolog contain spread viru
help current infect patient recov exampl
share gilead rose significantli monday investor
process news first confirm case
appear respond gilead
placebo-control trial remdesivir begin
china potenti gener treatment option
also test make chang
gilead fair valu estim time beyond gilead
name coverag -- like roch whose diagnost arm
coronaviru assay avail research use
yet approv -- could see tailwind need
mask soap commod hospit suppli like
demand howev assum signific long-
term financi impact outbreak unless
stay power sale tend revers
follow year limit impact valuat
effect addit suppli use prevent
spread virus tend commodity-lik product
limit abil firm retain excess
profit especi long term
feb world organ confirm
case vast major case
diagnos china sever countri
report hand case jan declar
coronaviru outbreak global health emerg
public health emerg intern concern
pheic signifi sever threat outsid china
within healthcar coverag think
biggest financi benefit could come firm
develop novel drug treat vaccin
prevent timelin regulatori approv
therapi highli uncertain vaccin even
manufactur quickli within month firm includ
smaller biotech like inovio pharma
firm like johnson johnson glaxo clinic trial would
like take month year safeti would
need verifi administ vaccin
healthi individu addit outbreak could
abat time vaccin deem safe prospect
treatment seem immedi promis
preliminari sign effect drug includ
proven effect relat coronaviru sar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
effect anim model sar anoth
kaletra proteas inhibitor
recommend china nation health commiss
treatment although benefit
use could minim multipl gener firm
alreadi manufactur drug intern market
donat kaletra suppli china gilead
jan new england journal medicin publish
detail account treatment first confirm
 patient whose worsen condit
appar revers given nucleotid analog
remdesivir seventh day hospit earli last
week howev remdesivir enter clinic trial
wuhan hospit whether drug
could approv time treat signific number
patient outbreak uncertain assum
even approv month drug would like see
biggest benefit potenti stockpil futur
outbreak although avail gener treatment
option malaria treatment chloroquin hiv booster
ritonavir seem inhibit viru accord scientist
wuhan institut virolog drug donat
make us cautiou assum multi-billion-dollar sale
similar roch tamiflu stockpil tamiflu
pandem stockpil sale peak chf billion
avian flu also hit chf billion swine flu
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
launch allergan deal remain track
report third-quart result larg line
expect dont expect major chang
fair valu estim continu view firm
under-valued market like fulli appreci
next-gener immunolog cancer drug howev
despit strength new drug continu
view narrow moat lower wide moat
peer group averag larg due heavi biosimilar
pressur immunolog drug humira next four
quarter total sale increas oper
strong humira sale new product launch
offset intern biosimilar pressur humira
trend continu next two year dont
expect signific pressur top line
 humira biosimilar like launch howev
base strong efficaci expect abbvi next
gener immunolog drug off-set
humira headwind robust recent launch skyrizi
psoriasi rinvoq rheumatoid arthriti gener
million respect drug
launch slightli behind drug similar
mechan action market larg abbvi
like leverag strong formulari entrench
humira gain favor posit new drug
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
outsid
continu show robust growth expect
continu sever year blood cancer drug imbruvica
venclexta hold lead efficaci competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
threat emerg especi astra calquenc
decemb expect abbvi
entrench hard displac
allergan acquisit remain track
close deal first quarter like follow
divest allergan brazikumab zenpep
competitor abbvi skyrizi creon respect
appeas anti-trust regul
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
